BOSTON–(BUSINESS WIRE)–binx health, a healthcare technology and diagnostics company, announced today the appointment of Jack Crowley as Chief Financial Officer (CFO). Crowley brings deep industry expertise in life sciences and demonstrated results in successful initial and secondary public offerings, capital structure enhancements, analyst collaboration, and investor relations.
“We are thrilled to welcome Jack to our leadership team,” said Jeff Luber, binx CEO. “Whether at PricewaterhouseCoopers, Thermofisher Scientific, Biogen, Lantheus Medical Imaging, or PGDx, Jack has consistently demonstrated the ability to build great finance teams, lead in high-growth environments, and deliver on commitments, quarter after quarter. It’s these talents, and his clear sense of purpose, that will help us in delivering on our vision of ‘everywhere care.’”
“binx health has a vision for healthcare delivery that addresses current gaps in healthcare equity and healthcare access,” said Crowley. “This is a unique and transformational approach. I am appreciative of the opportunity and excited to work with this strong team to help realize this vision and expand upon it.”
Before joining binx health, Crowley was the CFO of Ora, Inc, a global leader in full service ophthalmic research. Jack also served as CFO at Personal Genome Diagnostics and Lantheus Medical Imaging and has held management-level finance positions with Biogen, Thermofisher Scientific and PricewaterhouseCoopers. Crowley is a CPA, MBA and a graduate of University of Massachusetts and Westfield State University. During his career Crowley has distinguished himself as a results-driven finance executive while working for Fortune 500 and private equity backed companies.
About binx health
binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop. The Company works with large corporate partners and institutions who have access to large patient populations and have a significant interest in delivering or facilitating better healthcare to provide access to and enable more streamlined delivery of diagnostic testing and care. Its omnichannel platform includes the point-of-care io platform, which puts central-lab quality testing solutions in the hands of clinicians everywhere, and the Company’s suite of physician-mediated and medical guideline-driven, at-home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital integration capability to those unable or unwilling to visit a clinic location.
binx’s io platform is the first ever FDA-cleared, CLIA-waived point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in about thirty minutes. Its platform is highly flexible, easy-to-use, and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. For more information, visit www.binx.com.
